Amin Khademi, Clemson University
Abstract
Identifying the right dose is one the most important decisions in drug development. Significant evidence has recently become available that emphasizes the role of patient covariates in optimal dose, i.e., a dose that is optimal for a patient group may be harmful for others. A key step towards personalized (precision) medicine is our ability to design efficient and fair clinical trials to investigate the optimal dose for each patient type. However, current methods do not consider patient covariates in optimal design of dose-finding clinical trials. In this talk we discuss the challenges that are involved in extending the standard methods for designing adaptive dose-finding clinical trials and how we can address them.
Full announcement at: MIE Events